Table 1.
Patient baseline and disease characteristics
| Characteristic | PALO (N = 136) | NEPA100 (N = 135) | NEPA200 (N = 137) | NEPA300 (N = 135) | APR + OND (N = 134) |
|---|---|---|---|---|---|
| Gender (%) | |||||
| Male | 57.4 | 57.0 | 57.7 | 57.0 | 56.0 |
| Female | 42.6 | 43.0 | 42.3 | 43.0 | 44.0 |
| Median age (years) | 55.0 | 55.0 | 55.0 | 53.0 | 55.5 |
| Alcohol consumption (%) | |||||
| No | 58.1 | 58.5 | 59.1 | 54.1 | 56.0 |
| Rarely | 37.1 | 34.8 | 34.3 | 37.8 | 39.6 |
| Occasionally | 4.4 | 6.7 | 6.6 | 8.1 | 4.5 |
| Cancer type (%) | |||||
| Lung/respiratory | 30.1 | 28.9 | 25.5 | 25.9 | 26.1 |
| Head and neck | 17.6 | 20.0 | 22.6 | 24.4 | 19.4 |
| Ovarian | 16.9 | 13.3 | 14.6 | 17.8 | 18.7 |
| Other urogenital | 13.2 | 14.1 | 18.2 | 11.1 | 13.4 |
| Gastric | 5.9 | 6.7 | 5.1 | 5.9 | 6.0 |
| Other GI | 7.4 | 3.0 | 5.1 | 4.4 | 7.5 |
| Breast | 2.9 | 8.1 | 4.4 | 5.9 | 5.2 |
| Other | 5.9 | 6.0 | 4.4 | 4.4 | 3.7 |
| Karnofsky Index (%) | |||||
| 70% | 2.9 | 1.5 | 2.9 | 3.0 | 2.2 |
| 80% | 30.1 | 33.3 | 29.2 | 24.4 | 27.6 |
| 90% | 58.8 | 57.8 | 54.7 | 60.0 | 61.2 |
| 100% | 8.1 | 7.4 | 13.1 | 12.6 | 9.0 |
| Chemotherapya (%) | |||||
| Cisplatin alone | 15.4 | 15.6 | 14.6 | 14.1 | 14.9 |
| Concomitant low | 52.9 | 45.9 | 56.9 | 48.1 | 52.2 |
| Concomitant moderate or high | 31.6 | 38.5 | 28.5 | 37.8 | 32.8 |
aThe median cisplatin dose was 75 mg/m2 for each group.